Functional alterations in the neurotrophin, brain-derived neurotrophic factor (BDNF) have recently been implicated in the pathophysiology of schizophrenia. Furthermore, animal studies have indicated that several antipsychotic drugs have time-dependent (and differential) effects on BDNF levels in the brain. For example, our previous studies in rats indicated that chronic treatment with the conventional antipsychotic, haloperidol, was associated with decreases in BDNF (and other neurotrophins) in the brain as well as deficits in cognitive function (an especially important consideration for the therapeutics of schizophrenia). Additional studies indicate that haloperidol has other deleterious effects on the brain (eg increased apoptosis). Despite such limitations, haloperidol remains one of the more commonly prescribed antipsychotic agents worldwide due to its efficacy for the positive symptoms of schizophrenia and its low cost. Interestingly, the hematopoietic hormone, erythropoietin, in its recombinant human form rhEPO has been reported to increase the expression of BDNF in neuronal tissues and to have neuroprotective effects. Such observations provided the impetus for us to investigate in the present study whether co-treatment of rhEPO with haloperidol could sustain the normal levels of BDNF in vivo in rats and in vitro in cortical neuronal cultures and further, whether BDNF could prevent haloperidol-induced apoptosis through the regulation of key apoptotic/antiapoptotic markers. The results indicated that rhEPO prevented the haloperidol-induced reduction in BDNF in both in vivo and in vitro experimental conditions. The sustained levels of BDNF in rats with rhEPO prevented the haloperidol-induced increase in caspase-3 (po0.05) and decrease in Bcl-xl (po0.01) protein levels. Similarly, in vitro experiments showed that rhEPO prevented (po0.001) the haloperidol-induced neuronal cell death as well as the decrease in Bcl-xl levels (po0.01). These findings may have significant implications for the development of neuroprotective strategies to improve clinical outcomes when antipsychotic drugs are used chronically.
INTRODUCTION
The prevention and/or amelioration of the neuropathological events in schizophrenia is a major therapeutic objective, however, an equally important goal is to ensure that the major therapeutic agents used (ie the antipsychotics) do not exacerbate this pathology. The effects of typical antipsychotics have been compared to atypical antipsychotics on psychopathology and neuropathology in schizophrenia, and based on short-term studies; atypical antipsychotics have been suggested to have a more favorable profile (Lieberman et al, 2003; Jarskog and Lieberman, 2006; Kapur et al, 2005; Leucht et al, 2005) . However, several animal studies indicate that long-term exposure to both classes of antipsychotics can be associated with adverse neurochemical and cognitive effects (reviewed, Terry and Mahadik, 2007) . In addition, the large prospective clinical study, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) indicated few significant advantages of typical antipsychotics over the representative conventional agent, perphenazine, when dropout rates (ostensibly due to intolerable side effects, lack of efficacy, etc) were considered. Further analyses of CATIE results indicated no significant difference between the two antipsychotic classes on psychosocial functioning in patients with chronic schizophrenia (Swartz et al, 2007) .
A growing area of investigation within the field of schizophrenia research is the role of neurotrophins in the both pathophysiology and therapeutics of the illness. For example, deficits in brain-derived neurotrophic factor (BDNF) signaling have been implicated in the pathogenesis of schizophrenia (reviewed by Shoval and Weizman, 2005; Buckley et al, 2007) as having elevations of apoptotic proteins (eg proapoptotic triggers) that may result from alterations in neurotrophins. The support for this hypothesis is based upon reports of significant alterations of the proteins Bcl-2 and Bax (specifically the Bax/Bcl-2 ratio) in brain regions that are known to be important to the symptomatology of the schizophrenia, such as temporal cortex (Jarskog et al, 2004) . Interestingly, short-term rodent studies have indicated an upregulation of antiapoptotic markers following treatment with olanzapine and clozapine (He et al, 2004; Bai et al, 2004) , but showed increased activation of caspase-3, an apoptotic marker, with chronic use of both typical and atypical antipsychotics (Jarskog et al, 2007) . Other studies in rodents have indicated that typical and atypical antipsychotics can have favorable or unfavorable effects on brain levels of BDNF (and other neurotrophins such as nerve growth factor) depending on the length of treatment (Alleva et al, 1996; Parikh et al, 2004a, b, c; ; reviewed by Terry and Mahadik, 2007) .
Among the various antipsychotics, haloperidol (HAL, a conventional or typical agent) continues to be widely prescribed worldwide due to higher potency and lower cost compared to many other antipsychotics, despite the possibility of adverse side effects. In addition, it appears to be among the least desirable agents from the standpoint of its temporal effects on neurotrophins in the brain (see Terry and Mahadik, 2007) . Accordingly, we have developed the hypothesis that the adjunctive use of neurotrophic compounds might provide neuroprotective effects and limit the adverse side effects associated with drugs like HAL. The direct delivery of neurotrophins (themselves) like BDNF to the brain remains a major challenge, however, due to permeability of the blood-brain barrier. An alternative approach to directly administering BDNF is to increase BDNF activity in the brain by agents that can easily enter in the CNS. Interestingly, recombinant human EPO (rhEPO) treatment has recently been reported to have such effects (ie to increase the expression of BDNF in the brain; Zhang et al, 2006) . Furthermore, several studies have shown that rhEPO is a potent neuroprotective agent against neural dysfunction resulting from a variety of neural insults that involve increased apoptosis (Sakanaka et al, 1998; Siren et al, 2001a; Dzietko et al, 2004; Spandou et al, 2004) .
The expression of erythropoietin (EPO) and its receptors have also been shown in cultured neurons and astrocytes in vitro, and rhEPO has been found to be neuroprotective in a variety of situations, including hypoxia and oxidative stress in vivo (Bernaudin et al, 1999 (Bernaudin et al, , 2000 Brines et al, 2000; Siren et al, 2001b; Marti, 2004) . Furthermore, a recent study by Ehrenreich et al, 2007 has shown that rhEPO improves cognitive functions in chronic schizophrenic patients. We recently reported that HAL and olanzapine have distinct temporal effects on the expression of EPO and its receptor in adult rat brain . Our data indicated that 14 days of HAL treatment increased the levels of EPO and its receptor in hippocampus and striatum, but their levels decreased below control values by 45 days of treatment, whereas olanzapine treatment sustained their increased levels at 45 days. These changes were in parallel to the neuropathological changes reported earlier in rats (Mahadik et al, 1988; Terry et al, 2002 Terry et al, , 2003 . These studies strongly indicate that rhEPO may prevent HAL-induced reduction in BDNF levels in the brain and thus allow BDNF to provide neuroprotection through apoptotic regulation. Such animal data provide an initial proof of concept for the potential use of rhEPO as an adjunctive approach to combat adverse effects of chronic antipsychotic therapy in human patients.
In the present study, co-treatment of rhEPO with HAL was studied to determine effects on the levels of BDNF in both in vivo and in vitro experiments. We also determined whether changes in BDNF levels after HAL alone or cotreatment with rhEPO were associated with changes in various apoptotic markers (Bcl-2, Bcl-xl, Bax, and caspase-3). 
MATERIALS AND METHODS

Animals
Drug Treatments in Rats
Animals were housed one per cage under a 12-h light/12-h dark cycle and at constant temperature (251C) and humidity. They were allowed free access to food and water. Haloperidol (Sigma Chemical Company, St Louis, MO) was dissolved in 0.1 M acetic acid and subsequently diluted daily (1 : 100) with tap water to administer the final daily dose of drug (diluted drug solution replaced drinking water). The amount of drug intake was measured daily, and adjustments were made depending upon the fluid consumed and weight of the animals. This method was preferred over multiple intramuscular injections to maintain more constant drug levels and to reduce stress and neuromuscular damage. Rats (N ¼ 6-8 per group) were administered HAL, HAL and rhEPO, or vehicle for 6 weeks. The HAL dose (2.0 mg/kg/ day) was selected based on previous studies where this dose was found to establish clinically relevant (Baldessarini et al, 1988) steady-state plasma levels in the rat . This dose is also comparable to the optimal dose to cause pharmacological effects (Skarsfeldt, 1996; Didriksen, 1995; Bymaster et al, 1996) . The schedule of HAL administration was selected based on several studies by us and others in which differences in behavioral as well as pharmacological effects were seen after 45 days of treatment in rats (Parikh et al, 2004a, b, c; Terry et al, 2004; Pillai et al, 2005; Angelucci et al, 2000; Dawson et al, 2001) . rhEPO (500 U/kg; Epoetin alfa, Eprex, Cilag) was administered intraperitoneally three times per week for 6 weeks. Tap water containing 0.1 M acetic acid was used for control group to assure that unanticipated effect of the vehicle was not present. All animals were monitored for change in body weight and food intake as possible adverse effects of the treatment.
Tissue Sample Preparation
At the end of treatment, rats were killed by decapitation, and the anterior right medial cortex from experimental and control rats were separately dissected and homogenized in ice-cold buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 1% Nonidet P-40, and 1% sodium deoxycholate) supplemented with protease inhibitor cocktail (Sigma) containing 104 mM AEBSF, 0.08 mM aprotinin, 2 mM leupeptin, 4 mM bestatin, 1.5 mM pepstatin A, and 1.4 mM E-64. After 15-min incubation period on ice, the extracts were clarified by centrifugation at 14 000 r.p.m. for 15 min at 41C and stored at À701C. Protein concentrations were determined by the bicinchoninic acid (BCA Protein Assay Kit, Sigma).
Brain-Derived Neurotrophic Factor Immunoassay
Brain-derived neurotrophic factor protein was measured with a conventional sandwich ELISA using the BDNF Emax ImmunoAssay System (Promega, Madison, WI, USA) according to the protocol of the manufacturer.
In Vitro Experiments
All cell-culture reagents, sera, and media were obtained from Invitrogen (Carlsbad, CA, USA).
Cerebral Cortical Neuronal Cultures
Mouse cortical neurons were cultured as described previously (Dhandapani et al, 2003) . Briefly, cerebral cortices from CD-1 murine embryos (E15) were aseptically dissected and plated at 3.5 Â 10 5 cells per well on polyethyleneiminecoated 24-well plates. Neurons were cultured in Neurobasal medium supplemented with B27, 2 mM L-glutamine, and antibiotics (Invitrogen). On the third day in vitro (DIV3), media was replaced with Neurobasal supplemented with B27 minus antioxidants, glutamine, and antibiotics. Purified neuronal cultures were routinely 497% neurons, as assessed by MAP-2 immunostaining. Neurons were used for treatments between DIV 5 and 7.
Drug Treatments of Cortical Neurons in Culture
The optimum dose and time of exposure of rat cortical neurons to HAL was determined by treating neurons with various concentrations of HAL (10, 20, 40, 80 , and 100 mM) for different time periods (6, 12, 24 , and 48 h). Neuroprotective experiments were done using 30 pM rhEPO and 50 mM HAL as the optimum dose. Cells were pretreated with rhEPO for 24 h and then continued either on rhEPO (EPO) or on rhEPO plus HAL (co-treatment, EPO + HAL) for the next 24 h. Cells were then harvested for either cell viability assay or for analysis of BDNF and apoptotic proteins. Each treatment was done in four wells, and each experiment was repeated three times by independent investigators.
Determination of Neuronal Cell Viability in Culture
Neuronal cell viability in culture was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay, as described by Dhandapani et al (2003) . Briefly, following treatments, MTT (5 mg/ml in phenol red-free RPMI-1640) was added to each well for 4 h at 371C. Following incubation, formazan salts were dissolved in acidic isopropanol and absorbance was measured using a Synergy HT plate reader (Bio-Tek, Winooski, VT) at 570 nm using a reference wavelength of 900 nm. All readings were compared with the control treatment group, which represented 100% viability.
Immunostaining for Neuronal Morphology with MAP-2 Antibody
Cortical neuronal cultures were fixed with 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS) for 30 min and rinsed three times with PBS. Nonspecific sites were blocked, and cells were then rinsed two times with 1% normal goat serum (NGS) and 1% bovine serum albumin (BSA) in PBS for 10 min. Cultures were incubated with rabbit polyclonal MAP-2 (Chemicon) (dilution of 1 : 500 with 1% NGS/1% BSA in PBS) overnight at 41C. Secondary antibody (Cy3-conjugated goat anti-rabbit IgG (1 : 500)) was incubated for 60 min at room temperature in 1% NGS + 1% BSA in PBS. After washing, images were captured using a Leica TCS-NT microscope.
Preparation of Neuronal Cell Lysates
Following treatments in culture, cells were washed in PBS and collected in ice-cold lysis buffer (250 mM sucrose, 50 mM Tris-HCl, pH 7.5, 25 mM KCl, 0.5 mM phenylmethylsulfonyl fluoride, 0.9 mM sodium butyrate, 1.0 mM sodium orthovanadate, and 1% protease inhibitor cocktail, Sigma). Protein concentration was determined by the bicinchoninic acid method (BCA Protein Assay Kit, Sigma).
Western Blot Analysis of Apoptotic Markers
Equal amounts of protein were resolved in SDS-polyacrylamide gels and transferred electrophoretically onto a nitrocellulose membrane (Bio-Rad). Membranes were blocked for 1 h in TBST (10 mM Tris-HCl, pH 8.0, 138 mM NaCl, 2.7 mM KCl, and 0.05% Tween 20) and 5% nonfat milk and incubated overnight with anti-sera directed against cleaved caspase-3 (1 : 200; Santa Cruz Biotech), Bax (1 : 250; Santa Cruz Biotech.), Bcl-2 (1 : 250; Santa Cruz Biotech), Bcl-xl (1 : 500; Santa Cruz Biotech), or b-actin (1 :250; Sigma). After washing with TBST, the membranes were incubated for 1 h with horseradish peroxidaseconjugated anti-rabbit or anti-mouse anti-sera in TBST and 3% nonfat milk. The membranes were washed again with TBST, and proteins were visualized by enhanced chemiluminescence. The optical density of each band was determined using Quantity One software (Bio-Rad) after normalizing to the expression of b-actin.
Caspase-3 Activity Assay
Caspase-3 activity was measured spectrophotometrically using the substrate N-acetyl-Asp-Glu-Val-Asp-p-nitroanilide (DEVD-pNa) in cortical homogenates according to the manufacturer's protocol (Caspase-3 Cellular Activity Assay Kit, Calbiochem, San Diego, CA). Specific activity of DEVDpNa cleavage for each sample was calculated by measuring the slope of the linear portion of the absorbance vs time graph, and expressed as pmol pNa/min/mg total protein.
Statistical Analysis
Results were expressed as means±SEM of five replicates of the same treatment and from 2 to 3 experiments done at different times using different sets of animals. The effect of different treatments was analyzed using a one-way analysis of variance (ANOVA) followed by post hoc Dunnett's multiple comparison test. A p-value of o0.05 was considered to be significant.
RESULTS
In Vivo Studies in Rats
rhEPO prevents HAL-induced decrease in BDNF levels in rat cerebral cortex. Continuous HAL treatment for 6 weeks significantly decreased BDNF protein levels compared to vehicle treatment (Figure 1 ; F ¼ 20.113, df ¼ 2, 30, p ¼ 0.002). EPO co-treatment prevented the HALassociated decrease in the BDNF protein levels (po0.001 vs HAL) and also significantly increased BDNF levels above vehicle treatment (po0.05 vs vehicle).
rhEPO prevents HAL-induced changes in apoptotic markers in rat cerebral cortex. The levels of Bcl-xl protein, an antiapoptotic marker, were significantly decreased after HAL treatment (Figure 2a ; F ¼ 16.441, df ¼ 2, 30, p ¼ 0.004) and were unchanged or slightly increased with rhEPO cotreatment (Figure 2a ; EPO + HAL) as compared to vehicletreated rats. However, the levels of another antiapoptotic marker, Bcl-2 (Figure 2b) , and the apoptotic marker, Bax protein (Figure 2c ), did not change with either HAL treatment alone or with rhEPO co-treatment (EPO + HAL). 
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As a result, the Bax/Bcl-xl ratio, indicative of increased apoptosis, was significantly increased in HAL-treated cortex (Figure 2d ; F ¼ 10.85, df ¼ 2, 30, p ¼ 0.003), whereas rhEPO co-treatment maintained the ratio to values in vehicletreated cortex samples.
rhEPO prevents HAL-induced changes in caspase-3 protein levels and enzymatic activity in rat cerebral cortex. The level of cleaved caspase-3 protein determined by western blot analysis was very low in the vehicle-treated samples (Figure 3a ; VEH). However, this increased significantly (by 65%) after 6 weeks of HAL treatment (Figure 3a ; HAL; F ¼ 10.636, df ¼ 2, 30, p ¼ 0.011). rhEPO co-treatment markedly prevented the increase of caspase-3, which did not differ from the VEH-treated levels.
The enzymatic activity of caspase-3 was also measured in cortical samples from rats treated with HAL alone or in combination with rhEPO. HAL treatment for 6 weeks induced a significant increase (Figure 3b ; HAL; po0.05 vs VEH) in caspase-3 activity. The specific activity of caspase-3 was B230% higher in HAL compared to VEH-treated rats. EPO prevented the increase in caspase-3 activity associated with HAL treatment (Figure 3b ; EPO + HAL), which was significantly lower (po0.05) than HAL but not statistically higher than VEH.
In Vitro Studies rhEPO co-treatment prevents the primary cortical neurons from HAL-induced cell death. Figure 4a shows the dosedependent effect of HAL (HAL10, HAL50, and HAL100) on neuronal cell survival and indicates that 24 h exposure of 50 mM HAL (HAL50) induced approximately 50% of neuronal death (F ¼ 35.665, df ¼ 5, 36, po0.001). Cotreatment with 30 pM of rhEPO (EPO30 + HAL50) significantly increased (po0.001 vs HAL50) the neuronal survival against HAL toxicity. A lower dose (3 pM) of rhEPO (EPO3 + HAL50) showed a smaller protective effect. Figure 4b shows representative photomicrographs of cortical neurons in culture with various treatments. The untreated cells (CON) appeared as healthy neurons with well-established neurite outgrowth. HAL treatment (50 mM) for 24 h resulted in massive loss of neurites and shrinkage or loss of cell bodies. rhEPO-treated cells (EPO) appeared very healthy, with large-size neuronal cell bodies even compared to CON. rhEPO co-treatment (EPO + HAL) substantially protected the cellular morphology from HAL toxicity.
rhEPO prevents HAL-induced decrease in BDNF expression. Exposure of primary cortical neurons to 50 mM HAL for 24 h significantly decreased the level of BDNF protein 
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A Pillai et al ( Figure 5 ; F ¼ 73.016, df ¼ 3, 36, po0.001) as compared to untreated cells. rhEPO (30 pM) alone was able to increase the BDNF levels (po0.05) relative to untreated cells. However, rhEPO co-treatment prevented the HAL-associated decrease in BDNF protein levels (po0.001 vs HAL) and also significantly increased BDNF levels above the levels in the untreated cells (po0.001 vs vehicle).
Role of BDNF in rhEPO-induced neuroprotection against HAL-induced cell death. The role of BDNF in rhEPOinduced neuroprotection against HAL-induced neuronal cell death was investigated in primary cortical neurons. Neurons were exposed for 24 h to 30 pM rhEPO in the presence or absence of a neutralizing anti-BDNF antibody and then challenged with 50 mM HAL (Figure 6 ). HAL treatment reduced cell survival to B50% ( Figure 6 , lane 1; rhEPO prevents HAL treatment-induced decrease in Bcl-xl protein levels. Exposure of primary cortical neurons to 50 mM HAL for 24 h significantly decreased the protein level Figure 4 Erythropoietin (EPO) protects cortical neurons from haloperidol (HAL)-induced cell death. Cortical neurons were preincubated for 24 h with 3 and 30 pM concentrations rhEPO, and then exposed to 10, 50, and 100 mm concentrations of HAL (HAL10, HAL50, and HAL100, respectively) for 24 h. MTT assay was performed to test the cell viability. (a) EPO (30 pM, EPO30), but not 3 pM EPO (EPO3), significantly protected cortical neurons from HAL toxicity. Values are mean ± SE of five independent experiments. ***po0.001 vs control (100%) and + + + po0.01 vs HAL50; ANOVA followed by post hoc Dunnett's multiple comparison test. (b) . Representative photographs of cortical neurons stained with MAP2. The treatment groups are neurons treated with vehicle (CON), 50 mM HAL, 30 pM rhEPO (EPO), or preincubation with 30 pM rhEPO for 24 h and then treated with 50 mM HAL for next 24 h (EPO + HAL). 
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DISCUSSION
This study is the first to report a neuroprotective effect of rhEPO against HAL-induced apoptosis and a possible underlying mechanism. This mechanism involves EPOmediated increased levels of BDNF and changes in key BDNF-mediated antiapoptotic and apoptotic molecules in vivo and in vitro. The findings include: (1) rhEPO cotreatment with HAL was able to prevent the HAL-induced reduction in BDNF very effectively (a well-established antiapoptotic neurotrophic factor) protein levels in vivo and in vitro, (2) the neuroprotective role of BDNF in rhEPO was further confirmed by reduced neuronal survival by rhEPO when BDNF was neutralized by a specific antibody, (3) the HAL-induced decrease in BDNF levels was associated with a decrease in Bcl-xl levels and an increase in caspase-3 levels, which were prevented by rhEPO cotreatment, and (4) the Bax/Bcl-xl ratio was increased with HAL treatment, an effect that was normalized by rhEPO co-treatment.
Our data are consistent with previous reports that HAL has cytotoxic effects in vivo and in vitro in various cell types, including primary neurons (Behl et al, 1995; Sagara, 1998; Noh et al, 2000) . A number of mechanisms have been suggested for HAL-induced cytotoxicity, including necrotic and apoptotic mechanisms. The increased caspase-3 activity in cultured neurons continuously exposed to HAL for 24 h is consistent with the earlier reports in rats (Ukai et al, 2004; Jarskog et al, 2007) . Some studies have reported a caspase-independent pathway-mediated cell death by HAL (Wei et al, 2006; Crawford and Bowen, 2002) . In the present study we observed (in addition to an increase in caspase-3 levels) a decrease in the antiapoptotic protein, Bcl-xl (thus resulting in a high Bax/Bcl-xl ratio), but no change in Bcl-2 levels in cortex after 45 days of HAL exposure in rats. Jarskog et al (2000) have also reported increased activity of caspase-3 but no change in Bcl2 in rat frontal cortex following 4 weeks of HAL administration. The increased Bax/Bcl-xl ratio has been also reported in rat hippocampus and caudate-putamen following HAL administration (Post et al, 2002) .
EPO-induced neuroprotection is now well documented and thought to involve several mechanisms, one of which is Role of brain-derived neurotrophic factor (BDNF) in EPOinduced neuroprotection against haloperidol (HAL) toxicity. Cortical neurons were preincubated ( + ) or not (À) for 24 h with 30 pM rhEPO, rhEPO + 15 mg/ml antibody against BDNF (Ab BDNF), or rhEPO + 15 mg/ml IgY and then exposed to 50 mM HAL for 24 h. MTT assay was performed to test the cell viability. EPO-induced neuroprotection against HAL was significantly prevented by Ab BDNF. Cell viability is expressed as percentage of that measured in vehicle-treated neurons (dotted line). Values are mean ± SE of five independent experiments. ***po0.001 vs treatment 1; *po0.05 vs treatment 2, and + + + po0.001 vs treatment 4; ANOVA followed by post hoc Dunnett's multiple comparison test. Erythropoietin prevents haloperidol-induced neurotoxicity A Pillai et al the recruitment of molecules involved in neuroprotective signaling. Importantly, increased BDNF expression has been shown to mediate rhEPO-induced neuroprotection in various toxicity models (Dzietko et al, 2004; Viviani et al, 2005) . In the present study, we found prevention of the HAL-induced reduction in BDNF protein levels by rhEPO co-treatment. This co-treatment approach is, therefore, important since earlier studies from our own and other laboratories have shown that long-term (44 weeks) HAL treatment causes reduction in BDNF levels Angelucci et al, 2000; Dawson et al, 2001 ) and EPO levels in rat brain. The argument that the neuroprotective role of rhEPO against HAL-induced cell death (in our study) was likely mediated via its effects on BDNF was supported by the reduced cortical neuronal cell survival induced by a specific neutralizing BDNF antibody. Although the mechanism(s) underlying rhEPO-mediated neuroprotection are likely complex, one possibility involves the activation of PI3K-Akt to limit neuronal apoptosis (Maiese et al, 2004) . Akt may then phosphorylate cAMP responsive element-binding protein (CREB), leading to increased BDNF promoter activity and gene expression (Hayes et al, 1997; Shieh and Ghosh, 1999; Zhang et al, 2006) . In a separate study, we have reported that HAL exposure of cortical neuronal cultures reduced the Akt activation and pretreatment with rhEPO maintained the levels of activated Akt (Pillai et al, 2007a) . Akt is also known to induce the expression of survival genes such as Bcl-2 and Bcl-xl, by activating CREB and nuclear factor-kB (Downward, 2004) . Though the ability of rhEPO to maintain BDNF levels may limit several adverse cellular effects of HAL, including a reduction in brain glutathione levels, decreased antioxidant enzyme expression, enhanced oxidative stress (Behl et al, 1995; Pillai et al, 2007b; Sagara, 1998; Shivakumar and Ravindranath, 1992; Yokoyama et al, 1998) , and changes in cholinergic neuronal markers (Mahadik et al, 1988; Terry et al, 2003) since BDNF has already been found to prevent changes in these molecules (Mattson et al, 1995) .
We selected 6 weeks of HAL exposure in this study as the chronic treatment period in rats to simulate the chronic continuous treatment in patients (ie 6 weeks in rats with a lifespan of approximately 35 months equals 43 years in humans with 470 years of lifespan). Such a time period of HAL exposure in humans has been associated with a broad range of adverse neuropathological (basal ganglia and diffuse loss of dendritic and synaptic loss) and neurobehavioral (extrapyramidal symptoms, tardive dyskinesia) effects (Cadet and Lohr, 1989; Jeste and Wyatt, 1982; Casey, 1985) . We selected the 2.0 mg/kg/day dose of HAL in our studies since this dose was previously found to establish clinically relevant (Baldessarini et al, 1988) steadystate plasma levels in the rat . It is also important to point out that under similar dosing conditions the levels of HAL were reported to be 10 times higher in the brain than plasma levels (Kornhuber et al, 2006) . Also, the half-lives for elimination from brain were 7.9 as opposed to o24 h from the plasma. The concentration of HAL used in cultures was established for optimum time and effect.
In conclusion, the findings of this study may have considerable clinical relevance based on the important role of BDNF in schizophrenia and the reported reductions in brain BDNF levels in rodent studies with long-term antipsychotic treatment . Therefore, sustained or increased brain BDNF by exogenous rhEPO co-treatment has the potential to prevent and/or reverse neuropathological events in schizophrenia (Glantz et al, 2006) . In support of this possibility, a recent clinical add-on therapy, rhEPO with antipsychotic medication, showed significant improvement in cognitive function in chronic schizophrenia patients (Ehrenreich et al, 2007) . In addition, rhEPO has therapeutic advantages over other neurotrophic factors in terms of delivery to their target cells in the brain and clinical tolerability (Abicht and Lochmuller, 1999; Horina et al, 1991) . Although there are some concerns regarding the hematopoietic activity of rhEPO, derivatives of rhEPO are being developed that have potent neuroprotective activity with no hematopoietic activity (Erbayraktar et al, 2003) .
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